Who is sponsoring NCT03269695?

NCT03269695 is sponsored by Pfizer.

What condition does NCT03269695 study?

NCT03269695 studies Ulcerative Colitis.

What drugs are being tested in NCT03269695?

Interventions: PF-06687234, Placebo.

What is the status of NCT03269695?

NCT03269695 is currently TERMINATED.

Last reviewed 2021-12-28 · How we verify

Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.

NCT03269695 PHASE2 TERMINATED Results posted

The purpose of this study is to determine if PF-06687234 is effective and safe as add-on therapy to infliximab in subjects with active ulcerative colitis who are not in remission.

Details

Lead sponsor	Pfizer
Phase	PHASE2
Status	TERMINATED
Enrolment	20
Start date	Wed Dec 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Jan 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Ulcerative Colitis

Interventions

PF-06687234
Placebo

Countries

Italy, Belgium, Serbia, Saudi Arabia, Israel, Germany, South Korea, Australia, United States, Turkey (Türkiye)